Intuitive Surgical (ISRG) Delivers Impressive Q4 Results, Driven by Strong Demand for da Vinci Systems

Intuitive Surgical (NASDAQ: ISRG), a global leader in robotic-assisted surgery, reported strong financial results for the fourth quarter of 2024, driven by robust demand for its da Vinci surgical systems. The company's revenue and earnings growth were fueled by increased procedure volume and a larger installed base of systems.



Key highlights from Intuitive Surgical's Q4 2024 financial results include:

* Revenue of $2.41 billion, up 25% year-over-year (YoY), surpassing analysts' expectations of $2.25 billion.
* GAAP net income attributable to Intuitive Surgical, Inc. of $686 million, or $1.88 per diluted share, compared to $606 million, or $1.69 per diluted share, in Q4 2023.
* Non-GAAP net income of $805 million, or $2.21 per diluted share, compared to $574 million, or $1.60 per diluted share, in the same period last year.
* Worldwide da Vinci procedures grew approximately 18% compared to the fourth quarter of 2023, driven by strong demand in the United States and international markets.
* The company placed 493 da Vinci surgical systems, including 174 da Vinci 5 systems, in the fourth quarter of 2024, compared to 415 systems in the same period last year.
* Systems revenue increased by 36% YoY, reflecting a lower mix of leased systems and higher da Vinci system average selling prices.
* Instruments and accessories revenue grew by 23% YoY, primarily driven by growth in da Vinci and Ion procedure volume and customer buying patterns.



Intuitive Surgical's strong performance in Q4 2024 was driven by several key factors:

1. Increased da Vinci Procedures: The company reported an 18% increase in da Vinci procedures compared to the fourth quarter of 2023, indicating strong demand for its robotic surgical systems.
2. Growth in Systems Revenue: Intuitive Surgical's systems revenue increased by 36% YoY, reflecting a lower mix of leased systems and higher da Vinci system average selling prices.
3. Expansion of da Vinci Surgical System Installed Base: The company placed 493 da Vinci surgical systems in the fourth quarter of 2024, including 174 da Vinci 5 systems, contributing to its revenue growth.
4. Growth in Instruments and Accessories Revenue: The company's instruments and accessories revenue increased by 23% YoY, primarily driven by growth in da Vinci and Ion procedure volume and customer buying patterns.

Intuitive Surgical's impressive Q4 2024 results demonstrate the company's continued growth and dominance in the robotic-assisted surgery market. As the demand for minimally invasive surgical procedures continues to rise, Intuitive Surgical is well-positioned to capitalize on this trend and maintain its market leadership. Investors should closely monitor the company's progress as it continues to innovate and expand its offerings in the robotic-assisted surgery space.